1. Pardoll DM. The blockade of immune checkpoints in cancer im
munotherapy. Nat Rev Cancer. 2012;12(4):252-264.
2. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint
blockade. Science. 2018;359(6382):1350-1355.
3. Willsmore ZN, Coumbe BGT, Crescioli S, et al. Combined
anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of
melanoma and immune mechanisms of action. Eur J Immunol.
2021;51(3):544-556.
4. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus
ipilimumab in advanced non-small-cell lung cancer. N Engl J Med.
2019;381(21):2020-2031.
5. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse
events associated with immune checkpoint blockade. N Engl J
Med. 2018;378(2):158-68.
6. Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min
L. Endocrine toxicity of cancer immunotherapy treating immune
checkpoints. Endocr Rev. 2019;40(1):17-65.
7. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of
endocrine dysfunction following the use of different immune check
point inhibitor regimens: a systematic review and meta-analysis.
JAMA Oncol. 2018;4(2):173-182.
8. Takahashi Y. Mechanisms in endocrinology: autoimmune hypo
pituitarism: novel mechanistic insights. Eur J Endocrinol.
2020;182(4):R59-R66.
9. Arima H, Iwama S, Inaba H, et al. Management of immune-related
adverse events in endocrine organs induced by immune checkpoint
inhibitors: clinical guidelines of the Japan Endocrine Society.
Endocr J. 2019;66(7):581-586.
10. Marshall S, Kizuki A, Kitaoji T, et al. Type 1 diabetes, ACTH defi
ciency, and hypothyroidism simultaneously induced by nivolumab
therapy in a patient with gastric cancer: a case report. Case Rep
Oncol. 2020;13(3):1185-1190.
11. Okahata S, Sakamoto K, Mitsumatsu T, et al. Fuluminant type 1
diabetes associated with isolated ACTH deficiency induced by anti-
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
programmed cell death 1 antibody-insight into the pathogenesis of
autoimmune endocrinopathy. Endocr J. 2019;66(4):295-300.
Saisho Y, Kou K, Tanaka K, et al. Postprandial serum C-peptide to
plasma glucose ratio as a predictor of subsequent insulin treatment
in patients with type 2 diabetes. Endocr J. 2011;58(4):315-322.
Funakoshi S, Fujimoto S, Hamasaki A, et al. Utility of indices using
C-peptide levels for indication of insulin therapy to achieve good
glycemic control in Japanese patients with type 2 diabetes. J
Diabetes Investig. 2011;2(4):297-303.
Inaba H, Ariyasu H, Iwakura H, et al. Comparative analysis of hu
man leucocyte antigen between idiopathic and anti-PD-1 antibody
induced isolated adrenocorticotropic hormone deficiency: a pilot
study. Clin Endocrinol (Oxf). 2019;91(6):786-792.
Kawabata Y, Ikegami H, Awata T, et al. Differential association of
HLA with three subtypes of type 1 diabetes: fulminant, slowly pro
gressive and acute-onset. Diabetologia. 2009;52(12):2513-2521.
Yano S, Ashida K, Sakamoto R, et al. Human leucocyte antigen
DR15, a possible predictive marker for immune checkpoint
inhibitor-induced secondary adrenal insufficiency. Eur J Cancer.
2020;130:198-203.
Menconi F, Monti MC, Greenberg DA, et al. Molecular amino acid
signatures in the MHC class II peptide-binding pocket predispose to
autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci
U S A. 2008;105(37):14034-14039.
Inaba H, Ariyasu H, Iwakura H, et al. Distinct clinical features and
prognosis between persistent and temporary thyroid dysfunctions
by immune-checkpoint inhibitors. Endocr J. 2021;68(2):231-241.
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel
in advanced squamous-cell non-small-cell lung cancer. N Engl J
Med. 2015;373(2):123-135.
Robert C, Schachter J, Long G V, et al. Pembrolizumab versus ipi
limumab in advanced melanoma. N Engl J Med. 2015;372(26):
2521-2532.
Albarel F, Castinetti F, Brue T. Management of endocrine disease:
immune check point inhibitors-induced hypophysitis. Eur J
Endocrinol. 2019;181(3):R107-R118.
Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of
ipilimumab-induced hypophysitis, a common adverse event of the
anti-CTLA-4 antibody in melanoma. Eur J Endocrinol.
2015;172(2):195-204.
Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypo
physitis: a detailed longitudinal analysis in a large cohort of patients
with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):
4078-85.
Kanie K, Iguchi G, Bando H, et al. Two cases of atezolizumabinduced hypophysitis. J Endocr Soc. 2017;2(1):91-95.
Yamazaki N, Kiyohara Y, Uhara H, et al. Phase II study of ipilimu
mab monotherapy in Japanese patients with advanced melanoma.
Cancer Chemother Pharmacol. 2015;76(5):997-1004.
Ohara N, Kobayashi M, Ohashi K, et al. Isolated adrenocortico
tropic hormone deficiency and thyroiditis associated with nivolu
mab therapy in a patient with advanced lung adenocarcinoma: a
case report and review of the literature. J Med Case Rep.
2019;13(1):88.
Paepegaey AC, Lheure C, Ratour C, et al. Polyendocrinopathy re
sulting from pembrolizumab in a patient with a malignant melan
oma. J Endocr Soc. 2017;1(6):646-649.
Min L, Ibrahim N. Ipilimumab-induced autoimmune adrenalitis.
Lancet Diabetes Endocrinol. 2013;1(3):e15.
Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4
antibody) causes regression of metastatic renal cell cancer associ
ated with enteritis and hypophysitis. J Immunother. 2007;30(8):
825-830.
Andrioli M, Pecori Giraldi F, Cavagnini F. Isolated corticotrophin
deficiency. Pituitary. 2006;9(4):289-295.
Imagawa A, Hanafusa T, Awata T, et al. Report of the committee of
the Japan Diabetes Society on the research of fulminant and acuteonset type 1 diabetes mellitus: new diagnostic criteria of fulminant
Downloaded from https://academic.oup.com/jes/article/7/3/bvad002/6972399 by Kobe University Library user on 14 March 2023
autoimmune thyroid disease [41]. In this case series, we could
not perform CTLA-4 gene analysis. Further studies are re
quired, including this polymorphism, to clarify the pathology
of ICI-induced combined endocrinopathies.
In conclusion, we presented 3 cases of complicated com
bined endocrinopathies comprising hypophysitis and T1DM
due to ICIs. The use of anti-PD-1 antibodies may be associated
with the occurrence of combined endocrinopathies. HLA
genotyping was performed in all 3 cases, and the hypophysitisor T1DM-associated haplotype was frequently found
(HLA*A 24:02). Further case accumulation and pathogenic
investigations are needed to identify the significant features
of this extremely rare occurrence of combined endocrinopa
thies as irAEs.
Journal of the Endocrine Society, 2023, Vol. 7, No. 3
Journal of the Endocrine Society, 2023, Vol. 7, No. 3
32.
33.
34.
36.
37. Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids
for the treatment of ipilimumab-induced hypophysitis is associated
with reduced survival in patients with melanoma. Cancer.
2018;124(18):3706-3714
38. Grangeon M, Tomasini P, Chaleat S, et al. Association between
immune-related adverse events and efficacy of immune checkpoint
inhibitors in non-small-cell lung cancer. Clin Lung Cancer.
2019;20(3):201-207.
39. Kim HI, Kim M, Lee SH, et al. Development of thyroid dysfunction
is associated with clinical response to PD-1 blockade treatment
in patients with advanced non-small cell lung cancer.
Oncoimmunology. 2017;7(1):e1375642.
40. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and
haplotypic associations defined by allelic DNA typing at HLA class
I and class II loci in the Japanese population. Tissue Antigens.
2000;56(6):522-529.
41. Ikegami H, Awata T, Kawasaki E, et al. The association of CTLA4
polymorphism with type 1 diabetes is concentrated in patients compli
cated with autoimmune thyroid disease: a multicenter collaborative
study in Japan. J Clin Endocrinol Metab. 2006;91(3):1087-1092.
Downloaded from https://academic.oup.com/jes/article/7/3/bvad002/6972399 by Kobe University Library user on 14 March 2023
35.
type 1 diabetes mellitus (2012). J Diabetes Investig. 2012;3(6):
536-539.
Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage:
insulin-dependent diabetes induced with checkpoint inhibitors.
Diabetes. 2018;67(8):1471-1480.
Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced
by immune checkpoint inhibitors: a 10-year assessment. Expert Rev
Endocrinol Metab. 2019;14(6):381-398.
Tsang VHM, McGrath RT, Clifton-Bligh RJ, et al. Checkpoint
inhibitor-associated autoimmune diabetes is distinct from
type 1 diabetes. J Clin Endocrinol Metab. 2019;104(11):
5499-5506.
Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint in
hibitors: an emerging cause of insulin-dependent diabetes. BMJ
Open Diabetes Res Care. 2019;7(1):e000591.
Kobayashi T, Iwama S, Yasuda Y, et al. Pituitary dysfunction in
duced by immune checkpoint inhibitors is associated with better
overall survival in both malignant melanoma and non-small cell
lung carcinoma: a prospective study. J Immunother Cancer.
2020;8(2):e000779.
11
...
論文の公開元へ
